Microsatellite instability and PD-L1 expression in sarcomas: current evidence and clinical perspectives

Area of Science:

• Oncology
• Immunology
• Biomarker Research

Background:

• Sarcomas are complex cancers with limited treatment options.
• Biomarkers like Microsatellite Instability (MSI) and Programmed Death-Ligand 1 (PD-L1) are underexplored in sarcomas.
• Lymphovascular Invasion (LVI) may influence immune response in sarcomas.

Purpose of the Study:

• To analyze the incidence, clinical relevance, and immunotherapy implications of MSI and PD-L1 in sarcomas.
• To explore the role of LVI in modulating sarcoma immune response.
• To propose a framework for sarcoma diagnostics and treatment using these biomarkers.

Main Methods:

• Comprehensive literature review of MSI and PD-L1 in sarcoma.
• Analysis of immunohistochemistry (IHC) and next-generation sequencing (NGS) data.
• Review of recent clinical trials in sarcoma immunotherapy.

Main Results:

• MSI-high (MSI-H) sarcomas are rare but correlate with higher tumor mutational burden (TMB) and neoantigen load, suggesting checkpoint blockade sensitivity.
• Concurrent MSI and PD-L1 expression, found in ~2-5% of sarcomas, may identify an immunogenic subgroup for personalized immunotherapy.
• LVI-positive sarcomas might upregulate PD-L1 as an immune escape mechanism.

Conclusions:

• Dual assessment of MSI and PD-L1, alongside LVI status, is crucial for improving sarcoma prognostication and guiding immunotherapy.
• A proposed framework incorporating MSI, IHC, PD-L1, and LVI can enhance precision oncology in sarcoma care.
• Further translational research is needed to leverage these biomarkers for improved sarcoma treatment outcomes.